- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15.01. | Immix Biopharma - Shifting the ALA treatment paradigm with CAR-T | 242 | Edison Investment Research | We review Immix Biopharma as it enters 2025, following the streamlining of its strategic priorities towards r/r ALA as the lead target indication for its CAR-T asset, NXC-201. The commencement of the... ► Artikel lesen | |
| 07.01. | Immix Biopharma, Inc.: Immix Biopharma Accelerates Enrollment in U.S. AL Amyloidosis Trial of NXC-201 CAR-T | 244 | GlobeNewswire (Europe) | Successfully dosed 6 patients in safety run-in segment, now accelerating enrollmentPositive data from first four patients announced December 2024NXC-201 is the only one-time CAR-T therapy in development... ► Artikel lesen | |
| 26.12.24 | Immix Biopharma-Direktor Jason Hsu erwirbt Aktien im Wert von 104.358 US-Dollar | 4 | Investing.com Deutsch | ||
| IMMIX BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 19.12.24 | Immix Biopharma, Inc.: Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloidosis | 125 | GlobeNewswire (Europe) | All four patients treated with NXC-201 normalized their disease markers within 30 days of dosing, of which, two are already classified as complete responders (CR), and the remaining two are bone marrow... ► Artikel lesen | |
| 16.12.24 | Immix Biopharma meldet vielversprechende Ergebnisse der CAR-T-Therapie | 3 | Investing.com Deutsch | ||
| 16.12.24 | Immix Biopharma, Inc.: Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL Amyloidosis | 107 | GlobeNewswire (Europe) | Chimeric antigen receptor T-cell (CAR-T) cell therapy NXC-201 is a novel approach to treat relapsed/refractory AL Amyloidosis NXC-201 demonstrated compelling clinical activity, rapid and deep complete... ► Artikel lesen | |
| 10.12.24 | Immix Biopharma reports strong CAR-T therapy results for AL Amyloidosis | 3 | Investing.com | ||
| 10.12.24 | Immix Biopharma, Inc.: Immix Biopharma Announces 75% Complete Response Rate (n=16); 31.5 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2024 | 108 | GlobeNewswire (Europe) | 75% (12/16) complete response (CR) rate observed in standard of care (Dara-CyBorD) relapsed/refractory AL Amyloidosis patients with median 4 lines of prior therapy in updated Phase 1/2 data as of December... ► Artikel lesen | |
| 25.11.24 | Immix Biopharma, Inc.: Immix Biopharma Presents Positive NXC-201 Clinical Data at 66th American Society of Hematology (ASH) Annual Meeting in 16 Relapsed/Refractory AL Amyloidosis Patients | 2 | GlobeNewswire (USA) | ||
| 12.11.24 | Immix Biopharma, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 04.10.24 | Immix Biopharma - US CAR-T trial progresses to dose expansion | 339 | Edison Investment Research | Immix Biopharma's US-based NEXICART-2 trial continues to make steady progress through the clinic, with the company reporting that the trial has advanced to the dose expansion level of 450m cells, after... ► Artikel lesen | |
| 03.10.24 | H.C. Wainwright confident in Immix stock growth with progress in NEXICART-2 CAR-T trial | 1 | Investing.com | ||
| 03.10.24 | H.C. Wainwright zuversichtlich für Immix-Aktienwachstum aufgrund von Fortschritten in der NEXICART-2 CAR-T-Studie | 6 | Investing.com Deutsch | ||
| 02.10.24 | Immix Biopharma, Inc.: Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort Dose Level in U.S. AL Amyloidosis Trial NEXICART-2 | 169 | GlobeNewswire (Europe) | Now dosing at dose expansion level of 450 million NXC-201 CAR+T cells. First cohort at 150 million CAR+T cells already successfully completed Each of these two doses have produced complete responses... ► Artikel lesen | |
| 30.09.24 | Immix Biopharma stock hits 52-week low at $1.51 amid market challenges | 1 | Investing.com | ||
| 30.09.24 | Immix Biopharma-Aktie erreicht 52-Wochen-Tief bei 1,51 US-Dollar | 1 | Investing.com Deutsch | ||
| 20.09.24 | Immix Biopharma-Aktie erreicht 52-Wochen-Tief bei 1,74 US-Dollar | - | Investing.com Deutsch | ||
| 20.09.24 | Immix Biopharma stock hits 52-week low at $1.74 amid market challenges | 1 | Investing.com | ||
| 19.09.24 | Immix Biopharma gains AL Amyloidosis expert for advisory board | 2 | Investing.com | ||
| 19.09.24 | Immix Biopharma gewinnt AL-Amyloidose-Experten für wissenschaftlichen Beirat | 1 | Investing.com Deutsch |
Seite:
1 2 3 Weiter >>
41 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDIGENE | 1,338 | +2,00 % | Original-Research: Medigene AG (von First Berlin Equity Research GmbH): Buy | Original-Research: Medigene AG - from First Berlin Equity Research GmbH 16.01.2025 / 14:05 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group. The issuer is solely... ► Artikel lesen | |
| BB BIOTECH | 40,000 | +0,25 % | BB Biotech, BioNTech, BYD, Deutz, Deutsche Telekom, Nel ASA - 4investors Aktien Top-News | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| QIAGEN | 45,855 | +0,58 % | Qiagen schüttet clever aus | Bei Qiagen profitieren Anleger nicht nur von verbesserten fundamentalen Aussichten: Das Unternehmen schüttet erneut Kapital über einen Reverse Stock Split aus - insgesamt 300 Mio. US-Dollar. Die Venloer... ► Artikel lesen | |
| NOVAVAX | 8,405 | -0,65 % | Novavax Aktie: BRUTALE PROGNOSE zwingt Anleger zum Handeln. So sollten Sie HEUTE reagieren! | ||
| STRYKER | 378,50 | -0,32 % | Stryker lässt die europäische Konkurrenz weit hinter sich | Das Thema Medizintechnik wird in Frankfurt derzeit nicht allzu hoch gehangen. Die Aktienperformance der deutschen und europäischen Unternehmen aus der Branche ist bestenfalls bescheiden. Doch in den... ► Artikel lesen | |
| ILLUMINA | 136,46 | +0,65 % | Illumina: If There Is a Monster in Loch Ness, This Geneticist Will Find It | NORTHAMPTON, MA / ACCESSWIRE / January 16, 2025 / IlluminaProfessor Neil Gemmell has a new plan to expand environmental DNA collection from the legendary lakeOriginally published on Illumina News CenterThe... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 40,100 | +1,01 % | CRISPR Therapeutics Stock Falls 34% in a Year: Time to Buy or Sell? | ||
| AAP IMPLANTATE | 1,870 | +2,75 % | HV-Kalender: Aktionärs-Versammlungen u.a. bei aap implantate, bioXXmed, Deutsche Wohnen, HanseYachts, ThyssenKrupp, Vonovia | Einmal jährlich müssen sich Aufsichtsrat und Vorstand einer Gesellschaft den Aktionären stellen: Die Hauptversammlung ist das höchste Organ einer Aktiengesellschaft und vergleichbarer Unternehmens-Formen.... ► Artikel lesen | |
| OCUGEN | 0,734 | +2,23 % | Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200-a Novel Integrin-Targeting Biologic for Diabetic Macular Edema | MALVERN, Pa., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 1,086 | +0,63 % | Sangamo To Regain Rights To Hemophilia Therapy After Pfizer's Decides To Terminate Collaboration | NEW YORK CITY (dpa-AFX) - Genomic medicine company Sangamo Therapeutics, Inc. (SGMO) Monday announced that it will regain development and commercialization rights to giroctocogene fitelparvovec... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 9,734 | +1,99 % | Intellia Loses 21.6% in a Week: How Should You Play the Stock? | ||
| SCORPIUS | - | - | XFRA CAPITAL ADJUSTMENT INFORMATION - 20.01.2025 | Das Instrument BRA AU000000BVS9 BRAVURA SOLUTIONS EQUITY wird cum Kapitalmassnahme gehandelt am 20.01.2025 und ex Kapitalmassnahme am 21.01.2025 The instrument BRA AU000000BVS9 BRAVURA SOLUTIONS EQUITY... ► Artikel lesen | |
| EDITAS MEDICINE | 1,155 | -0,13 % | Editas Medicine, Inc.: Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities | Achieved in vivo preclinical proof of concept of editing hematopoietic stem cells in non-human primates as a key step toward developing a novel in vivo treatment for sickle cell disease and beta thalassemia... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 7,200 | -1,37 % | BioCryst Pharmaceuticals, Inc.: BioCryst Announces Preliminary Full Year 2024 ORLADEYO (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y) | -ORLADEYO net revenue expected to be between $515-$535 million in 2025- -Total revenue (including RAPIVAB®) expected to be between $540-$560 million in 2025- -Company achieved operating profit in... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,582 | +10,65 % | Defence Therapeutics Inc.: Defence to Connect with Industry Leaders and Potential Partners During the JP Morgan Healthcare Conference in San Francisco. Plans to Expand the Next Generation of Radio-Immuno Conjugates in 2025 | Montreal, Quebec--(Newsfile Corp. - January 10, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company") a Canadian biopharmaceutical company developing radiopharmaceuticals... ► Artikel lesen |
IMMIX BIOPHARMA INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 1,990 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu IMMIX BIOPHARMA INC finden Sie auf Wallstreet Online.
